Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis

(2021) Matteo Lucchini et al.   JOURNAL OF NEUROLOGY

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)

(2021) Thomas W. Lategan et al.   CNS DRUGS

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

(2020) Robert T. Naismith et al.   CNS DRUGS

Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population

(2020) Giacomo Boffa et al.   CNS DRUGS

Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate

(2020) Daniel Wynn et al.   Multiple Sclerosis and Related Disorders

Factors associated with dimethyl fumarate-induced lymphopenia

(2019) Susana Sainz de la Maza et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence

(2019) Martin Diebold et al.   Multiple Sclerosis Journal

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

(2019) Michael J. Palte et al.   ADVANCES IN THERAPY

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

(2019) Fabian Sierra Morales et al.   JOURNAL OF NEUROLOGY

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study

(2018) Massimiliano Mirabella et al.   CNS DRUGS

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count

(2018) M. Baharnoori et al.   Multiple Sclerosis and Related Disorders

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

(2017) Robbert-Jan Gieselbach et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE)

(2016) U. Mrowietz et al.   BRITISH JOURNAL OF DERMATOLOGY

Dimethyl fumarate associated lymphopenia in clinical practice

(2014) Erin E Longbrake et al.   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE